Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EXEL 
Exelixis Inc (EXEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: EXEL (3-star) is a REGULAR-BUY. BUY since 27 days. Profits (-1.99%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 28.78% | Avg. Invested days 45 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.37B USD | Price to earnings Ratio 21.05 | 1Y Target Price 37.06 |
Price to earnings Ratio 21.05 | 1Y Target Price 37.06 | ||
Volume (30-day avg) 2786114 | Beta 0.57 | 52 Weeks Range 20.14 - 40.02 | Updated Date 04/2/2025 |
52 Weeks Range 20.14 - 40.02 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 24.04% | Operating Margin (TTM) 28.84% |
Management Effectiveness
Return on Assets (TTM) 14.64% | Return on Equity (TTM) 23.13% |
Valuation
Trailing PE 21.05 | Forward PE 16.53 | Enterprise Value 9264432965 | Price to Sales(TTM) 4.78 |
Enterprise Value 9264432965 | Price to Sales(TTM) 4.78 | ||
Enterprise Value to Revenue 4.27 | Enterprise Value to EBITDA 12.89 | Shares Outstanding 279880992 | Shares Floating 235903678 |
Shares Outstanding 279880992 | Shares Floating 235903678 | ||
Percent Insiders 1.84 | Percent Institutions 92.06 |
Analyst Ratings
Rating 3.95 | Target Price 34.47 | Buy 4 | Strong Buy 9 |
Buy 4 | Strong Buy 9 | ||
Hold 8 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Exelixis Inc
Company Overview
History and Background
Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California. It is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to treat cancers.
Core Business Areas
- Oncology Drug Development and Commercialization: Focuses on researching, developing, and commercializing innovative therapies for various types of cancer.
Leadership and Structure
Exelixis is led by Vicki L. Goodman, as the current CEO. The company has a traditional hierarchical structure with departments focusing on research, development, commercialization, and administration.
Top Products and Market Share
Key Offerings
- CABOMETYX (cabozantinib): A tyrosine kinase inhibitor (TKI) approved for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC). Revenue from Cabometyx is significant and the main driver of the company's success. Key competitors include therapies from Bristol Myers Squibb (BMY), Merck (MRK) and Pfizer (PFE).
- COMETRIQ (cabozantinib): An earlier formulation of cabozantinib approved for progressive, metastatic medullary thyroid cancer. Market share is smaller compared to CABOMETYX.
Market Dynamics
Industry Overview
The oncology drug market is characterized by high growth, driven by increasing cancer incidence and advancements in treatment options. It's highly competitive with numerous companies developing novel therapies.
Positioning
Exelixis is positioned as a mid-sized biopharmaceutical company with a strong focus on targeted cancer therapies. Its competitive advantage lies in its successful commercialization of CABOMETYX and ongoing research and development efforts.
Total Addressable Market (TAM)
The global oncology market is estimated to be over $200 billion. Exelixis is well-positioned to capture a share of the TAM, focusing on specific cancer types where CABOMETYX has demonstrated efficacy.
Upturn SWOT Analysis
Strengths
- Successful commercialization of CABOMETYX
- Strong pipeline of oncology drug candidates
- Experienced management team
- Strategic partnerships with major pharmaceutical companies
Weaknesses
- Reliance on a single key product (CABOMETYX)
- Competition from larger pharmaceutical companies
- Risk associated with clinical trial outcomes
- Potential for generic competition
Opportunities
- Expansion of CABOMETYX label to new indications
- Development and commercialization of new oncology drugs
- Strategic acquisitions and collaborations
- Growth in emerging markets
Threats
- Regulatory hurdles
- Pricing pressures
- Patent expirations
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
- ONCT
Competitive Landscape
Exelixis competes with larger pharmaceutical companies in the oncology market. Its advantage lies in its targeted therapies and focused approach, while its disadvantage is its smaller size and limited resources compared to its competitors.
Major Acquisitions
Aurigene Discovery Technologies Limited
- Year: 2019
- Acquisition Price (USD millions): 92.5
- Strategic Rationale: Expanded Exelixis's drug discovery capabilities and pipeline with novel oncology programs.
Growth Trajectory and Initiatives
Historical Growth: Exelixis has experienced significant growth in recent years, driven by the commercial success of CABOMETYX.
Future Projections: Analysts project continued growth for Exelixis, driven by further expansion of CABOMETYX and the potential approval of new drug candidates.
Recent Initiatives: Recent initiatives include expanding the CABOMETYX label, advancing the pipeline of oncology drug candidates, and forming strategic partnerships.
Summary
Exelixis is a biopharmaceutical company with a solid foundation built upon the success of CABOMETYX. The company's financial performance is strong, fueled by growing revenues and a healthy balance sheet. While the reliance on a single key product represents a risk, Exelixis is actively pursuing label expansions and advancing its pipeline to mitigate this concern. The company needs to be prepared for increased competition from large pharmaceutical companies.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
ONCT
Oncternal Therapeutics Inc
ONCT
Oncternal Therapeutics Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Exelixis Inc
Exchange NASDAQ | Headquaters Alameda, CA, United States | ||
IPO Launch date 2000-04-07 | CEO, President & Director Dr. Michael M. Morrissey Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1147 | Website https://www.exelixis.com |
Full time employees 1147 | Website https://www.exelixis.com | ||
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.